Skip to main content

Table 4 Comparisons of baseline/post/change between good vs poor responders in Cohort A

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Response

Good Response

Poor Response

Difference (Good - Poor)

Timepoints

Baseline

Post-treatment

Change (Post - Pre)

Baseline

Post-treatment

Change (Post - Pre)

Baseline

Post-treatment

Change

Blood biomarker

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SD)

Mean (±SE)

P-value$

Mean (±SE)

P-value$

Mean (±SE)

P-value$

WBC (×103 cells/μL)

9.2 (±3.7)

6.3 (±2.3)

−2.9 (±3.1)

7.2 (±3.4)

7.9 (±3.5)

0.6 (±2.6)

1.9 (±1.4)

0.092

− 1.6 (±1.1)

0.309

−3.5 (±1.1)

0.015

Hemoglobulin (gram/dL)

12.6 (±2.2)

12.6 (±1.8)

0.0 (±1.8)

12.2 (±1.7)

11.8 (±1.8)

−0.4 (±0.8)

0.4 (±0.8)

0.480

0.8 (±0.7)

0.210

0.3 (±0.6)

0.807

Platelet count (×103 cells/μL)

339.9 (±121.6)

248.7 (±96.1)

−91.3 (±103.8)

254.7 (±121.5)

234.5 (±96.5)

−20.2 (±95.9)

85.2 (±47.6)

0.092

14.1 (±37.7)

0.643

−71.1 (±39.5)

0.079

ANC (×103 cells/μL)

6.8 (±3.6)

4.4 (±2.3)

−2.5 (±3.2)

5.1 (±3.0)

6.2 (±3.3)

1.1 (±2.5)

1.7 (±1.3)

0.237

−1.9 (±1.1)

0.095

−3.6 (±1.1)

0.014

ALCs (×103 cells/μL)

1.4 (±0.7)

1.2 (±0.7)

−0.2 (±0.7)

1.2 (±0.9)

0.9 (±0.4)

−0.4 (±0.5)

0.2 (±0.3)

0.395

0.4 (±0.2)

0.078

0.2 (±0.3)

0.575

CD3 + CD4 + %

38.7 (±10.9)

39.4 (±8.8)

0.7 (±8.0)

43.3 (±11.2)

39.0 (±9.0)

−4.3 (±4.5)

−4.6 (±4.3)

0.276

0.4 (±3.5)

0.922

5.0 (±2.7)

0.100

CD3 + CD8 + %

23.9 (±9.3)

24.8 (±7.8)

0.9 (±3.9)

23.8 (±10.4)

23.2 (±10.9)

−0.6 (±2.2)

0.1 (±3.8)

0.806

1.6 (±3.6)

0.436

1.5 (±1.3)

0.234

CD3 + %

64.3 (±9.0)

66.0 (±8.0)

1.7 (±7.0)

67.8 (±12.0)

63.1 (±10.0)

−4.7 (±5.5)

−3.5 (±4.0)

0.357

2.9 (±3.5)

0.355

6.4 (±2.5)

0.041

CD3 + CD4+ count (cells/μL)

541.4 (±311.1)

466.3 (±213.0)

−75.1 (±314.4)

471.5 (±244.6)

344.9 (±179.5)

−126.5 (±94.8)

69.9 (±112.1)

0.592

121.4 (±78.4)

0.157

51.5 (±98.2)

0.592

CD3 + CD8+ count (cells/μL)

372.3 (±296.3)

307.7 (±232.8)

−64.6 (±234.0)

239.9 (±97.6)

184.1 (±88.6)

−55.8 (±30.2)

132.3 (±93.1)

0.321

123.6 (±74.0)

0.041

−8.7 (±71.4)

0.714

CD4/CD8 ratio

1.9 (±0.8)

1.8 (±0.8)

−0.1 (±0.6)

2.1 (±1.0)

2.1 (±1.2)

0.0 (±0.5)

−0.3 (±0.3)

0.527

−0.3 (±0.4)

0.527

−0.1 (±0.2)

0.788

CD4 plus CD8 count (cells/μL)

913.6 (±524.8)

774.0 (±407.0)

−139.6 (±507.4)

711.4 (±301.2)

529.0 (±227.2)

− 182.4 (±119.1)

202.3 (±175.8)

0.321

245.0 (±135.7)

0.039

42.7 (±156.7)

0.643

dNLR

3.8 (±3.8)

2.6 (±1.8)

−1.2 (±3.8)

2.8 (±1.0)

4.0 (±2.0)

1.2 (±1.6)

1.00 (±1.2)

0.575

−1.4 (±0.7)

0.033

−2.4 (±1.2)

0.027

  1. Abbreviation: SD Standard Deviation, SE Standard Error
  2. $P-values from Wilcoxon rank sum tests. Bold for statistical significance
Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us